Summary by Moomoo AI
HANSEN PHARMACEUTICAL GROUP CO., LTD. ANNOUNCED THAT ITS WHOLLY OWNED SUBSIDIARY HANSEN (SHANGHAI) HEALTH TECHNOLOGY CO., LTD. SIGNED AN EXCLUSIVE LICENSING AGREEMENT WITH POMIS BIOTECHNOLOGY (ZHUHAI) CO., LTD. ON MARCH 14, 2024. Under the agreement, Hansen acquired the rights to develop, manufacture and commercialize HS-20117 (PM1080) worldwide, a proprietary EGFR/cMet antibody currently in Phase I clinical trials. Johnson will make an initial payment of not more than RMB 50 billion and milestone payments based on development, registration and sales, as well as royalty fees based on net sales worldwide. This new global license will enrich Johnson's research pipeline and expand its impact in the field of oncology therapy. Pomis is a company focused on innovative biopharmaceutical development for malignant tumors and autoimmune diseases, and is not affiliated with Johnson. This License Agreement does not constitute any publicable transaction or connected transaction.